Back to Search Start Over

Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.

Authors :
Garcia-Recio S
Hinoue T
Wheeler GL
Kelly BJ
Garrido-Castro AC
Pascual T
De Cubas AA
Xia Y
Felsheim BM
McClure MB
Rajkovic A
Karaesmen E
Smith MA
Fan C
Ericsson PIG
Sanders ME
Creighton CJ
Bowen J
Leraas K
Burns RT
Coppens S
Wheless A
Rezk S
Garrett AL
Parker JS
Foy KK
Shen H
Park BH
Krop I
Anders C
Gastier-Foster J
Rimawi MF
Nanda R
Lin NU
Isaacs C
Marcom PK
Storniolo AM
Couch FJ
Chandran U
Davis M
Silverstein J
Ropelewski A
Liu MC
Hilsenbeck SG
Norton L
Richardson AL
Symmans WF
Wolff AC
Davidson NE
Carey LA
Lee AV
Balko JM
Hoadley KA
Laird PW
Mardis ER
King TA
Perou CM
Source :
Nature cancer [Nat Cancer] 2023 Jan; Vol. 4 (1), pp. 128-147. Date of Electronic Publication: 2022 Dec 30.
Publication Year :
2023

Abstract

The AURORA US Metastasis Project was established with the goal to identify molecular features associated with metastasis. We assayed 55 females with metastatic breast cancer (51 primary cancers and 102 metastases) by RNA sequencing, tumor/germline DNA exome and low-pass whole-genome sequencing and global DNA methylation microarrays. Expression subtype changes were observed in ~30% of samples and were coincident with DNA clonality shifts, especially involving HER2. Downregulation of estrogen receptor (ER)-mediated cell-cell adhesion genes through DNA methylation mechanisms was observed in metastases. Microenvironment differences varied according to tumor subtype; the ER <superscript>+</superscript> /luminal subtype had lower fibroblast and endothelial content, while triple-negative breast cancer/basal metastases showed a decrease in B and T cells. In 17% of metastases, DNA hypermethylation and/or focal deletions were identified near HLA-A and were associated with reduced expression and lower immune cell infiltrates, especially in brain and liver metastases. These findings could have implications for treating individuals with metastatic breast cancer with immune- and HER2-targeting therapies.<br /> (© 2022. The Author(s).)

Details

Language :
English
ISSN :
2662-1347
Volume :
4
Issue :
1
Database :
MEDLINE
Journal :
Nature cancer
Publication Type :
Academic Journal
Accession number :
36585450
Full Text :
https://doi.org/10.1038/s43018-022-00491-x